Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.39B P/E - EPS this Y -24.20% Ern Qtrly Grth -
Income -85.89M Forward P/E -13.64 EPS next Y -31.00% 50D Avg Chg -25.00%
Sales - PEG -0.79 EPS past 5Y - 200D Avg Chg 10.00%
Dividend N/A Price/Book 3.60 EPS next 5Y 40.00% 52W High Chg -46.00%
Recommedations 1.50 Quick Ratio 18.92 Shares Outstanding 100.49M 52W Low Chg 449.00%
Insider Own 5.78% ROA -23.47% Shares Float 89.57M Beta 0.54
Inst Own 78.25% ROE -34.79% Shares Shorted/Prior 12.92M/13.46M Price 13.91
Gross Margin - Profit Margin - Avg. Volume 2,851,827 Target Price 39.33
Oper. Margin - Earnings Date Apr 24 Volume 1,253,300 Change -1.77%
About Viking Therapeutics, Inc.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics, Inc. News
02/21/24 13 Best Booming Stocks to Buy Right Now
02/15/24 The 3 Biotech Stocks That Could Make Your February Unforgettable
02/14/24 7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution
02/10/24 President & CEO Brian Lian Sells 45,000 Shares of Viking Therapeutics Inc
02/09/24 President & CEO Brian Lian Sells 269,079 Shares of Viking Therapeutics Inc
02/08/24 Viking Therapeutics Charges To A Record High On An Update For Its Eli Lilly-Rivaling Obesity Drug
02/08/24 The 3 Most Undervalued Biotech Stocks to Buy in February 2024
02/08/24 Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2024 Earnings Call Transcript
02/08/24 Q4 2023 Viking Therapeutics Inc Earnings Call
02/07/24 Viking Therapeutics Inc (VKTX) Reports Year-End Financials Highlighting Strong Cash Position ...
02/07/24 Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
02/02/24 The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
02/01/24 President & CEO Brian Lian Sells 85,000 Shares of Viking Therapeutics Inc
01/31/24 Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024
01/31/24 President & CEO Brian Lian Sells 35,000 Shares of Viking Therapeutics Inc
01/30/24 We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow
01/29/24 2 Rising Biotechs That Could Become the Next Novo Nordisk
01/22/24 2 Stocks That Could Soar This Year: Are They Buys?
01/19/24 Director Sarah Rouan Sells 30,000 Shares of Viking Therapeutics Inc
01/09/24 The 3 Best Biotech Stocks to Buy in January 2024
VKTX Chatroom

User Image BeeDecay Posted - 58 minutes from now

$VKTX The fact that $MDGL gets a hit from Zealand Pharma's NASH results and $VKTX does not tells it all: Viking is priced for its obesity potential now whereas it was priced for NASH before. Viking having the broader pipeline pays off. Always be careful with one trick ponies. Ask the people over at $AMRN for instance. Well now - that's all fine but we have to be realistic: the obesity trials are super short and competition is fierce. That is a completely different story than NASH. Bottom line - the stock will move hard with the results of the SQ and oral on tap. Both positive as negative.

User Image hiphopgiraffi Posted - 17 minutes from now

$VKTX https://www.cnbc.com/2024/02/26/novo-nordisk-and-eli-lilly-rival-soars-26percent-after-promising-test-results.html?__source=iosappshare%7Ccom.apple.UIKit.activity.Message

User Image Rickerthestockpicker1 Posted - 10 minutes from now

$VKTX Very good

User Image BioRich Posted - 2 hours ago

$VKTX The scientific community backs this one. 40$ by Tuesday. Someone posted 100$ PT and I certainly don't disagree. $TERN will ride these coattails and have a PT of 23$ for them.

User Image TrustButVerifi Posted - 4 hours ago

$VKTX "Mounjaro supports weight loss of around 4% of body weight after one month." "Weight Loss of up to 7.8% From Baseline as well as Significant Liver Fat, Plasma Lipid Reductions following 28 Days of Treatment with VK2735"

User Image TrustButVerifi Posted - 5 hours ago

$VKTX Shares Short (Jan 31, 2024) 12.92 MILLION U CAN NOT BE SERIOUS! https://www.youtube.com/watch?v=nlGZmJrBtNc

User Image TrustButVerifi Posted - 5 hours ago

$VKTX For Newbies: in case u missed it! this is just phase 1. "VOLCANIC THERAPEUTICS" phase 1 on VK2735 subq once weekly x28 days (4 doses) reduction in mean body weight of up to 7.8% reduction of liver fat up to 47% from baseline reduction of liver fat in Non-Alcoholic Liver dis. pts up to 59% total cholesterol reduction of 21% reduction of LDL cholesterol 23%

User Image TrustButVerifi Posted - 5 hours ago

$VKTX Following is phase 1 with 10 mg dose, phase 2 coming out is 15 mg of VK2735. (LOCK UP YOUR FRKN SHARES) "Weight Loss of up to 7.8% From Baseline as well as Significant Liver Fat, Plasma Lipid Reductions following 28 Days of Treatment with VK2735"

User Image TrustButVerifi Posted - 5 hours ago

$VKTX This is a $100 stock minimum! Ozempic: On average, people lost 5.9% of their body weight at three months. VK2735 :Weight Loss of up to 7.8% From Baseline as well as Significant Liver Fat, Plasma Lipid Reductions following 28 Days of Treatment with VK2735

User Image Cjs2027 Posted - 5 hours ago

$VKTX is it too late to join this party?

User Image PKinUK16 Posted - 6 hours ago

$VKTX what are the 3 or 4 key indicators we should be looking for in the coming data? Obviously weight loss, adverse reaction rates/dropouts are the 2 big ones but what else could differentiate this one from NVO and LLY Thanks 🙏

User Image Mehmehmehmeh Posted - 9 hours ago

$MDGL $ALT $NVO $LLY $VKTX https://open.substack.com/pub/jlgas2023/p/the-case-for-madrigal-mdgl?r=1t0tw1&utm_medium=ios&utm_campaign=post

User Image jaros Posted - 9 hours ago

$VKTX https://www.nasdaq.com/articles/viking-therapeutics-vktx-price-target-increased-by-15.69-to-40.12

User Image BeyondtheCouch Posted - 11 hours ago

$VKTX read the analysts notes again and no need for Viking to wait for the follow up to release results. Could come sooner than you think.

User Image moonstocks777 Posted - 13 hours ago

$VKTX maybe vktx doesn’t need to present in may conference because they would have been bought by then and the acquirer(pfe/lilly?) will represent them.And with the news pfe filed a shelf few days ago possibly to do a big acquisition , you may start to put one and one together. Who knows?

User Image Excessive_ Posted - 13 hours ago

$ALT unfortunately $VKTX Will most likely set some records. Those records will be for stomach paralysis and lean muscle loss. GLUCAGON is the future. You can ask Lilly why they added it to their drug. If only they had the perfect ratio and euport. I would love to see how vktx would perform without titration. Time will tell. Enjoy the weekly options and volatility they bring.

User Image StockPhotoApe Posted - 14 hours ago

$ALT lol can all y'all please leave the $VKTX board alone? 🤣 Especially since they've been eating our lunch lately.

User Image fsu1 Posted - 15 hours ago

$VKTX https://www.businessinsider.com/us-economy-faster-growth-ozempic-glp-1-weight-loss-drugs-2024-2 See if this link is better than the last one.

User Image DG20 Posted - 15 hours ago

$VKTX $ALT It’s so interesting that a 7x market cap is “irrelevant” but a single meeting is ‘relevant’. Viking and Altimmune are NOT in competition you absolute moron, the market is humongous. If one goes up so will the other. Also considering that VKTX has a much larger MC it would make reasonable sense that YOU would want VKTX bought out first since it will expand your ability for a premium. ALT isn’t going to sell for $7B (as many suggest) without a precedent because that’s $140/share… BTW I own 17k shares of ALT before you accuse me of anything…

User Image fsu1 Posted - 15 hours ago

$VKTX https://www.msn.com/en-us/money/markets/the-more-americans-that-take-ozempic-the-faster-the-us-economy-will-grow-goldman-sachs-says/ar-BB1iLVjT

User Image JohnFromLong Posted - 15 hours ago

$VKTX

User Image TechnoViking Posted - 16 hours ago

$VKTX sorry but PFE is seeking a “shelf.” If they ask for a PayDay cash advance, then we put $ALT on watch brah 🤣🤣🤣 for real, get off the big boy board

User Image iPleadTheDip Posted - 16 hours ago

$ALT crazy how $VKTX wasn’t ask to speak amongst the industry leaders in this new space. Almost as if they’re…..irrelevant

User Image DG20 Posted - 18 hours ago

$VKTX They have access to insider information and the broader GLP market in general. They keep buying, hopefully they are aware of something positive coming soon 🔜…

User Image BeyondtheCouch Posted - 18 hours ago

$VKTX Fmr LLC increased its stake in Viking Therapeutics, Inc

User Image Vktxstorng Posted - 19 hours ago

$VKTX go @VKTX fam!🫶🏻

User Image Vktxstorng Posted - 20 hours ago

$VKTX 👇🏻👇🏻👇🏻

User Image Skipper6 Posted - 20 hours ago

$VKTX ...Just FYI folks, this came out about 1 hr ago from Simply Wall Street: -- Price target increased by 11% to US$40.89 Up from US$37.00, the current price target is an average from 10 analysts. -- New target price is 9.3% above last closing price of US$37.42. -- Stock is up 240% over the past year. Looking Fellow Longs! Skipper

User Image green_night Posted - 21 hours ago

$VKTX am I crazy for thinking that Brian had to know directionally what the data was indicating for these two releases? Is it possible the company didn’t have a good feel for what they were seeing? If he knew then you have to believe it is very positive given the tone of the call.

User Image moonstocks777 Posted - 22 hours ago

$VKTX The largest institution holding vktx shrs is fmr (Fidelity Investment) with a whopping 15M shares (15% ownership).

Analyst Ratings
Stifel Buy Feb 14, 24
Maxim Group Buy Feb 8, 24
Truist Securities Buy Dec 4, 23
Truist Securities Buy Oct 2, 23
Stifel Buy Aug 8, 23
HC Wainwright & Co. Buy Jul 27, 23
Truist Securities Buy Jun 27, 23
Raymond James Outperform May 17, 23
Oppenheimer Outperform May 16, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lian Brian President & CEO President & CEO Jan 31 Sell 24.7 85,000 2,099,500 2,264,882 01/31/24
Lian Brian President & CEO President & CEO Jan 31 Option 1.23 85,000 104,550 2,349,882 01/31/24
Lian Brian President & CEO President & CEO Jan 30 Sell 23.95 35,000 838,250 2,264,882 01/30/24
Lian Brian President & CEO President & CEO Jan 30 Option 1.23 35,000 43,050 2,299,882 01/30/24
Rouan Sarah Kathryn Director Director Jan 19 Sell 23.05 30,000 691,500 01/19/24
Rouan Sarah Kathryn Director Director Jan 19 Option 8.32 30,000 249,600 30,000 01/19/24
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Jan 03 Sell 17.9 15,000 268,500 180,730 01/04/24
Rowland Charles A Jr Director Director May 16 Option 1.08 40,000 43,200 70,000 05/18/23
Rowland Charles A Jr Director Director May 16 Sell 25 40,000 1,000,000 30,000 05/18/23
MACARTNEY LAWSON Director Director May 16 Sell 24 16,000 384,000 47,965 05/18/23
MACARTNEY LAWSON Director Director May 16 Option 1.19 16,000 19,040 63,965 05/18/23
Lian Brian President & CEO President & CEO May 01 Sell 22.45 45,000 1,010,250 2,197,963 05/01/23
MACARTNEY LAWSON Director Director Apr 24 Sell 22 16,000 352,000 47,965 04/24/23
MACARTNEY LAWSON Director Director Apr 24 Option 3.33 16,000 53,280 63,965 04/24/23
Lian Brian President & CEO President & CEO Apr 19 Sell 21.45 35,000 750,750 2,242,963 04/21/23
MACARTNEY LAWSON Director Director Apr 17 Sell 20 20,786 415,720 47,965 04/18/23
MACARTNEY LAWSON Director Director Apr 17 Option 8 20,786 166,288 68,751 04/18/23
Lian Brian President & CEO President & CEO Apr 17 Sell 20.45 155,000 3,169,750 2,277,963 04/18/23
Lian Brian President & CEO President & CEO Apr 17 Option 2.15 125,000 268,750 2,432,963 04/18/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Apr 17 Sell 20 12,500 250,000 287,763 04/18/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Apr 17 Option 13.07 12,500 163,375 300,263 04/18/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 17 Sell 20 7,500 150,000 149,279 04/18/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 17 Option 13.07 7,500 98,025 156,779 04/18/23
Lian Brian President & CEO President & CEO Apr 13 Sell 18.45 79,336 1,463,749 2,307,963 04/13/23
Lian Brian President & CEO President & CEO Apr 13 Option 1.88 54,336 102,152 2,387,299 04/13/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 11 Sell 18 97,839 1,761,102 149,279 04/13/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Apr 11 Option 6.12 97,839 598,775 190,823 04/13/23
Lian Brian President & CEO President & CEO Mar 30 Sell 17.43 243,352 4,241,625 2,232,963 04/03/23
Lian Brian President & CEO President & CEO Mar 30 Option 6.74 203,352 1,370,592 2,322,933 04/03/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Mar 30 Sell 17.5 161,940 2,833,950 147,778 04/03/23
ZANTE GREG Chief Financial Offi.. Chief Financial Officer Mar 30 Option 6.55 124,661 816,530 178,689 04/03/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 30 Option 9.92 72,200 716,224 261,895 04/03/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 28 Sell 15.5 237,805 3,685,978 261,895 03/30/23
Mancini Marianna Chief Operating Offi.. Chief Operating Officer Mar 28 Option 2.98 182,427 543,632 303,137 03/30/23